Enfusion (NYSE:ENFN) Hits New 12-Month High – Here’s What Happened

Enfusion, Inc. (NYSE:ENFN) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $10.78 and last traded at $10.67, with a volume of 16550 shares. The stock had previously closed at $10.62.

Analyst Ratings Changes

Separately, Stifel Nicolaus lifted their target price on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

Enfusion Price Performance

The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 268.82, a P/E/G ratio of 3.98 and a beta of 0.97. The business’s 50 day moving average is $9.64 and its 200 day moving average is $8.98.

Insider Transactions at Enfusion

In other news, COO Neal Pawar sold 21,801 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.03, for a total transaction of $218,664.03. Following the completion of the sale, the chief operating officer now owns 1,143,544 shares in the company, valued at approximately $11,469,746.32. The trade was a 1.87 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 36.44% of the company’s stock.

Institutional Investors Weigh In On Enfusion

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. RiverPark Advisors LLC acquired a new stake in shares of Enfusion during the second quarter worth about $68,000. Arizona State Retirement System acquired a new position in Enfusion during the second quarter worth approximately $86,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after acquiring an additional 1,315 shares during the period. Belvedere Trading LLC purchased a new position in shares of Enfusion during the third quarter worth approximately $114,000. Finally, Paloma Partners Management Co acquired a new position in shares of Enfusion in the 3rd quarter valued at $157,000. 81.05% of the stock is owned by hedge funds and other institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.